540 related articles for article (PubMed ID: 25927150)
1. Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
Dias JD; Norem K; Doorneweerd DD; Thurer RL; Popovsky MA; Omert LA
Arch Pathol Lab Med; 2015 May; 139(5):665-73. PubMed ID: 25927150
[TBL] [Abstract][Full Text] [Related]
2. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
[TBL] [Abstract][Full Text] [Related]
3. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Cuker A; Siegal DM; Crowther MA; Garcia DA
J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
[TBL] [Abstract][Full Text] [Related]
4. [Evidence of novel oral anticoagulants (NOAC)].
Kitazono T
Rinsho Shinkeigaku; 2013; 53(11):992-3. PubMed ID: 24291856
[TBL] [Abstract][Full Text] [Related]
5. Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Douketis J; Bell AD; Eikelboom J; Liew A
Can Fam Physician; 2014 Nov; 60(11):997-1001. PubMed ID: 25392439
[TBL] [Abstract][Full Text] [Related]
6. Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
Du S; Harenberg J; Krämer S; Krämer R; Wehling M; Weiss C
Ther Drug Monit; 2015 Jun; 37(3):375-80. PubMed ID: 25525760
[TBL] [Abstract][Full Text] [Related]
7. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system.
Bliden KP; Chaudhary R; Mohammed N; Muresan AA; Lopez-Espina CG; Cohen E; Raviv G; Doubleday M; Zaman F; Mathew B; Tantry US; Gurbel PA
J Thromb Thrombolysis; 2017 May; 43(4):437-445. PubMed ID: 28247290
[TBL] [Abstract][Full Text] [Related]
8. Novel oral anticoagulants--key messages for the angiologist.
Haas S; Spannagl M; Schellong SM
Vasa; 2012 May; 41(3):177-91. PubMed ID: 22565619
[TBL] [Abstract][Full Text] [Related]
9. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
10. Measuring Direct Oral Anticoagulants.
Gosselin RC; Douxfils J
Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
[TBL] [Abstract][Full Text] [Related]
11. The new oral anticoagulants: a challenge for hospital formularies.
Merli GJ
Hosp Pract (1995); 2012 Aug; 40(3):126-8. PubMed ID: 23086101
[TBL] [Abstract][Full Text] [Related]
12. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
[TBL] [Abstract][Full Text] [Related]
14. Are new oral anticoagulant dosing recommendations optimal for all patients?
Powell JR
JAMA; 2015 Mar; 313(10):1013-4. PubMed ID: 25756434
[No Abstract] [Full Text] [Related]
15. New orally active anticoagulants in critical care and anesthesia practice: the good, the bad and the ugly.
Sehgal V; Bajwa SJ; Bajaj A
Ann Card Anaesth; 2013; 16(3):193-200. PubMed ID: 23816673
[TBL] [Abstract][Full Text] [Related]
16. Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Destephan C; Waller AH; Patel RJ; Dhruvakumar S; Mazza V; Gerula C; Maher J; Kaluski E
Minerva Cardioangiol; 2012 Aug; 60(4):425-31. PubMed ID: 22858920
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
18. Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.
King CS; Holley AB; Moores LK
Chest; 2013 Apr; 143(4):1106-1116. PubMed ID: 23546483
[TBL] [Abstract][Full Text] [Related]
19. Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
Gallego P; Roldan V; Lip GY
Am J Respir Crit Care Med; 2013 Aug; 188(4):413-21. PubMed ID: 23672179
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.
Messerschmidt C; Friedman RJ
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):771-8. PubMed ID: 25767271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
